Browsing by Author "Lopalco G."

Now showing 1 - 8 of 8
  • No Thumbnail Available
    Item
    Development and implementation of the AIDA International Registry for patients with Behçet’s disease
    (Springer Science and Business Media Deutschland GmbH, 2022) Vitale A.; Della Casa F.; Ragab G.; Almaghlouth I.A.; Lopalco G.; Pereira R.M.; Guerriero S.; Govoni M.; Sfikakis P.P.; Giacomelli R.; Ciccia F.; Monti S.; Ruscitti P.; Piga M.; Lomater C.; Tufan A.; Opris-Belinski D.; Emmi G.; Hernández-Rodríguez J.; Şahin A.; Sebastiani G.D.; Bartoloni E.; Akkoç N.; Gündüz Ö.S.; Cattalini M.; Conti G.; Hatemi G.; Maier A.; Parronchi P.; Del Giudice E.; Erten S.; Insalaco A.; Li Gobbi F.; Maggio M.C.; Shahram F.; Caggiano V.; Hegazy M.T.; Asfina K.N.; Morrone M.; Prado L.L.; Dammacco R.; Ruffilli F.; Arida A.; Navarini L.; Pantano I.; Cavagna L.; Conforti A.; Cauli A.; Marucco E.M.; Kucuk H.; Ionescu R.; Mattioli I.; Espinosa G.; Araújo O.; Karkaş B.; Canofari C.; Sota J.; Laymouna A.H.; Bedaiwi A.A.; Colella S.; Giardini H.A.M.; Albano V.; Lo Monaco A.; Fragoulis G.E.; Kardas R.C.; Berlengiero V.; Hussein M.A.; Ricci F.; La Torre F.; Rigante D.; Więsik-Szewczyk E.; Frassi M.; Gentileschi S.; Tosi G.M.; Dagostin M.A.; Mahmoud A.A.-M.A.; Tarsia M.; Alessio G.; Cimaz R.; Giani T.; Gaggiano C.; Iannone F.; Cipriani P.; Mourabi M.; Spedicato V.; Barneschi S.; Aragona E.; Balistreri A.; Frediani B.; Fabiani C.; Cantarini L.
    Purpose of the present paper is to point out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients with Behçet’s disease (BD). The Registry is a clinical physician-driven non-population- and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental and socioeconomic information from BD patients; the Registry is based on the Research Electronic Data Capture (REDCap) tool, which is thought to collect standardised information for clinical real-life research, and has been realised to change over time according to future scientific acquisitions and potentially communicate with other existing and future Registries dedicated to BD. Starting from January 31st, 2021, to February 7th, 2022, 110 centres from 23 countries in 4 continents have been involved. Fifty-four of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 175 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 5993 fields organised into 16 instruments, including patient’s demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. The development of the AIDA International Registry for BD patients will facilitate the collection of standardised data leading to real-world evidence, enabling international multicentre collaborative research through data sharing, international consultation, dissemination of knowledge, inclusion of patients and families, and ultimately optimisation of scientific efforts and implementation of standardised care. Trial registration NCT05200715 in 21/01/2022. © 2022, The Author(s).
  • No Thumbnail Available
    Item
    Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome
    (Frontiers Media S.A., 2022) Vitale A.; Caggiano V.; Della Casa F.; Hernández-Rodríguez J.; Frassi M.; Monti S.; Tufan A.; Telesca S.; Conticini E.; Ragab G.; Lopalco G.; Almaghlouth I.; Pereira R.M.R.; Yildirim D.; Cattalini M.; Marino A.; Giani T.; La Torre F.; Ruscitti P.; Aragona E.; Wiesik-Szewczyk E.; Del Giudice E.; Sfikakis P.P.; Govoni M.; Emmi G.; Maggio M.C.; Giacomelli R.; Ciccia F.; Conti G.; Ait-Idir D.; Lomater C.; Sabato V.; Piga M.; Sahin A.; Opris-Belinski D.; Ionescu R.; Bartoloni E.; Franceschini F.; Parronchi P.; de Paulis A.; Espinosa G.; Maier A.; Sebastiani G.D.; Insalaco A.; Shahram F.; Sfriso P.; Minoia F.; Alessio M.; Makowska J.; Hatemi G.; Akkoç N.; Li Gobbi F.; Gidaro A.; Olivieri A.N.; Al-Mayouf S.M.; Erten S.; Gentileschi S.; Vasi I.; Tarsia M.; Mahmoud A.A.-M.A.; Frediani B.; Fares Alzahrani M.; Laymouna A.H.; Ricci F.; Cardinale F.; Jahnz-Rózyk K.; Tosi G.M.; Crisafulli F.; Balistreri A.; Dagostin M.A.; Ghanema M.; Gaggiano C.; Sota J.; Di Cola I.; Fabiani C.; Giardini H.A.M.; Renieri A.; Fabbiani A.; Carrer A.; Bocchia M.; Caroni F.; Rigante D.; Cantarini L.
    Objective: The aim of this paper is to present the AutoInflammatory Disease Alliance (AIDA) international Registry dedicated to Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome, describing its design, construction, and modalities of dissemination. Methods: This Registry is a clinical, physician-driven, population- and electronic-based instrument designed for the retrospective and prospective collection of real-life data. Data gathering is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain real-world evidence for daily patients' management. The Registry may potentially communicate with other on-line tools dedicated to VEXAS syndrome, thus enhancing international collaboration and data sharing for research purposes. The Registry is practical enough to be easily modified to meet future needs regarding VEXAS syndrome. Results: To date (April 22nd, 2022), 113 Centers from 23 Countries in 4 continents have been involved; 324 users (114 Principal Investigators, 205 Site Investigators, 2 Lead Investigators, and 3 data managers) are currently able to access the registry for data entry (or data sharing) and collection. The Registry includes 4,952 fields organized into 18 instruments designed to fully describe patient's details about demographics, clinical manifestations, symptoms, histologic details about skin and bone marrow biopsies and aspirate, laboratory features, complications, comorbidities, therapies, and healthcare access. Conclusion: This international Registry for patients with VEXAS syndrome will allow the achievement of a comprehensive knowledge about this new disease, with the final goal to obtain real-world evidence for daily clinical practice, especially in relation to the comprehension of this disease about the natural history and the possible therapeutic approaches. This Project can be found on https://clinicaltrials.gov NCT05200715. Copyright © 2022 Vitale, Caggiano, Della Casa, Hernández-Rodríguez, Frassi, Monti, Tufan, Telesca, Conticini, Ragab, Lopalco, Almaghlouth, Pereira, Yildirim, Cattalini, Marino, Giani, La Torre, Ruscitti, Aragona, Wiesik-Szewczyk, Del Giudice, Sfikakis, Govoni, Emmi, Maggio, Giacomelli, Ciccia, Conti, Ait-Idir, Lomater, Sabato, Piga, Sahin, Opris-Belinski, Ionescu, Bartoloni, Franceschini, Parronchi, de Paulis, Espinosa, Maier, Sebastiani, Insalaco, Shahram, Sfriso, Minoia, Alessio, Makowska, Hatemi, Akkoç, Li Gobbi, Gidaro, Olivieri, Al-Mayouf, Erten, Gentileschi, Vasi, Tarsia, Mahmoud, Frediani, Fares Alzahrani, Laymouna, Ricci, Cardinale, Jahnz-Rózyk, Tosi, Crisafulli, Balistreri, Dagostin, Ghanema, Gaggiano, Sota, Di Cola, Fabiani, Giardini, Renieri, Fabbiani, Carrer, Bocchia, Caroni, Rigante and Cantarini.
  • No Thumbnail Available
    Item
    A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project
    (Frontiers Media SA, 2023) Gaggiano C.; Del Bianco A.; Sota J.; Gentileschi S.; Ruscitti P.; Giacomelli R.; Piga M.; Crisafulli F.; Monti S.; Emmi G.; De Paulis A.; Vitale A.; Tarsia M.; Caggiano V.; Nuzzolese R.; Parretti V.; Fabiani C.; Lopalco G.; Maier A.; Cattalini M.; Rigante D.; Govoni M.; Li Gobbi F.; Guiducci S.; Parronchi P.; Marino A.; Ciccia F.; Maggio M.C.; Aragona E.; Bartoloni E.; Iagnocco A.; Viapiana O.; Sebastiani G.D.; Guerriero S.; Insalaco A.; Del Giudice E.; Conti G.; Barone P.; Olivieri A.N.; Brucato A.; Carubbi F.; Triggianese P.; Mauro A.; Tosi G.M.; Fonollosa A.; Giardini H.A.M.; Ragab G.; Tharwat S.; Hernández-Rodríguez J.; Sfikakis P.P.; Laskari K.; Karamanakos A.; Espinosa G.; Shahram F.; Direskeneli H.; Hinojosa-Azaola A.; Opris-Belinski D.; AlMaghlouth I.A.; Hatemi G.; Eksin M.A.; Önen F.; Więsik-Szewczyk E.; Akkoç N.; Tufan A.; Şahin A.; Erten Ş.; Ozen S.; Batu E.D.; Frediani B.; Balistreri A.; Cantarini L.
    Introduction: This paper describes the creation and preliminary results of a patient-driven registry for the collection of patient-reported outcomes (PROs) and patient-reported experiences (PREs) in Behçet’s disease (BD). Methods: The project was coordinated by the University of Siena and the Italian patient advocacy organization SIMBA (Associazione Italiana Sindrome e Malattia di Behçet), in the context of the AIDA (AutoInflammatory Diseases Alliance) Network programme. Quality of life, fatigue, socioeconomic impact of the disease and therapeutic adherence were selected as core domains to include in the registry. Results: Respondents were reached via SIMBA communication channels in 167 cases (83.5%) and the AIDA Network affiliated clinical centers in 33 cases (16.5%). The median value of the Behçet’s Disease Quality of Life (BDQoL) score was 14 (IQR 11, range 0–30), indicating a medium quality of life, and the median Global Fatigue Index (GFI) was 38.7 (IQR 10.9, range 1–50), expressing a significant level of fatigue. The mean Beliefs about Medicines Questionnaire (BMQ) necessity-concern differential was 0.9 ± 1.1 (range – 1.8–4), showing that the registry participants prioritized necessity belief over concerns to a limited extent. As for the socioeconomic impact of BD, in 104 out of 187 cases (55.6%), patients had to pay from their own pocket for medical exams required to reach the diagnosis. The low family socioeconomic status (p < 0.001), the presence of any major organ involvement (p < 0.031), the presence of gastro-intestinal (p < 0.001), neurological (p = 0.012) and musculoskeletal (p = 0.022) symptoms, recurrent fever (p = 0.002), and headache (p < 0.001) were associated to a higher number of accesses to the healthcare system. Multiple linear regression showed that the BDQoL score could significantly predict the global socioeconomic impact of BD (F = 14.519, OR 1.162 [CI 0.557–1.766], p < 0.001). Discussion: Preliminary results from the AIDA for Patients BD registry were consistent with data available in the literature, confirming that PROs and PREs could be easily provided by the patient remotely to integrate physician-driven registries with complementary and reliable information. Copyright © 2023 Gaggiano, Del Bianco, Sota, Gentileschi, Ruscitti, Giacomelli, Piga, Crisafulli, Monti, Emmi, De Paulis, Vitale, Tarsia, Caggiano, Nuzzolese, Parretti, Fabiani, Lopalco, Maier, Cattalini, Rigante, Govoni, Li Gobbi, Guiducci, Parronchi, Marino, Ciccia, Maggio, Aragona, Bartoloni, Iagnocco, Viapiana, Sebastiani, Guerriero, Insalaco, Del Giudice, Conti, Barone, Olivieri, Brucato, Carubbi, Triggianese, Mauro, Tosi, Fonollosa, Giardini, Ragab, Tharwat, Hernández-Rodríguez, Sfikakis, Laskari, Karamanakos, Espinosa, Shahram, Direskeneli, Hinojosa-Azaola, Opris-Belinski, AlMaghlouth, Hatemi, Eksin, Önen, Więsik-Szewczyk, Akkoç, Tufan, Şahin, Erten, Ozen, Batu, Frediani, Balistreri and Cantarini.
  • No Thumbnail Available
    Item
    Musculoskeletal manifestations in children with Behçet’s syndrome: data from the AIDA Network Behçet’s Syndrome Registry
    (Springer Science and Business Media Deutschland GmbH, 2023) Gaggiano C.; Maselli A.; Sfikakis P.P.; Laskari K.; Ragab G.; Hegazy M.T.; Laymouna A.H.; Lopalco G.; Almaghlouth I.A.; Asfina K.N.; Alahmed O.; Giardini Mayrink H.A.; Parente de Brito Antonelli I.; Cattalini M.; Piga M.; Sota J.; Gentileschi S.; Maggio M.C.; Opris-Belinski D.; Hatemi G.; Insalaco A.; Olivieri A.N.; Tufan A.; Karadeniz H.; Kardaş R.C.; La Torre F.; Cardinale F.; Marino A.; Guerriero S.; Ruscitti P.; Tarsia M.; Vitale A.; Caggiano V.; Telesca S.; Iannone F.; Parretti V.; Frassi M.; Aragona E.; Ciccia F.; Wiesik-Szewczyk E.; Ionescu R.; Şahin A.; Akkoç N.; Hinojosa-Azaola A.; Tharwat S.; Hernández-Rodríguez J.; Espinosa G.; Conti G.; Del Giudice E.; Govoni M.; Emmi G.; Fabiani C.; Balistreri A.; Frediani B.; Rigante D.; Cantarini L.
    This study aims to describe musculoskeletal manifestations (MSM) in children with Behçet’s syndrome (BS), their association with other disease manifestations, response to therapy, and long-term prognosis. Data were retrieved from the AIDA Network Behçet’s Syndrome Registry. Out of a total of 141 patients with juvenile BS, 37 had MSM at disease onset (26.2%). The median age at onset was 10.0 years (IQR 7.7). The median follow-up duration was 21.8 years (IQR 23.3). Recurrent oral (100%) and genital ulcers (67.6%) and pseudofolliculitis (56.8%) were the most common symptoms associated with MSM. At disease onset, 31 subjects had arthritis (83.8%), 33 arthralgia (89.2%), and 14 myalgia (37.8%). Arthritis was monoarticular in 9/31 cases (29%), oligoarticular in 10 (32.3%), polyarticular in 5 (16.1%), axial in 7 (22.6%). Over time, arthritis became chronic-recurrent in 67.7% of cases and 7/31 patients had joint erosions (22.6%). The median Behçet's Syndrome Overall Damage Index was 0 (range 0–4). Colchicine was inefficacious for MSM in 4/14 cases (28.6%), independently from the type of MSM (p = 0.46) or the concomitant therapy (p = 0.30 for cDMARDs, p = 1.00 for glucocorticoids); cDMARDs and bDMARDs were inefficacious for MSM in 6/19 (31.4%) and 5/12 (41.7%) cases. The presence of myalgia was associated with bDMARDs inefficacy (p = 0.014). To conclude, MSM in children with BS are frequently associated with recurrent ulcers and pseudofolliculitis. Arthritis is mostly mono- or oligoarticular, but sacroiliitis is not unusual. Prognosis of this subset of BS is overall favorable, though the presence of myalgia negatively affects response to biologic therapies. ClinicalTrials.gov Identifier: NCT05200715 (registered on December 18, 2021). © 2023, The Author(s).
  • No Thumbnail Available
    Item
    The Systemic Score May Identify Life-Threatening Evolution in Still Disease: Data from the GIRRCS AOSD-Study Group and the AIDA Network Still Disease Registry
    (John Wiley and Sons Inc, 2024) Ruscitti P.; Masedu F.; Vitale A.; Caggiano V.; Di Cola I.; Cipriani P.; Valenti M.; Mayrink Giardini H.A.; de Brito Antonelli I.P.; Dagostin M.A.; Lopalco G.; Iannone F.; Maria M.; Almaghlouth I.A.; Asfina K.N.; Ali H.H.; Ciccia F.; Iacono D.; Pantano I.; Mauro D.; Sfikakis P.P.; Tektonidou M.; Laskari K.; Berardicurti O.; Dagna L.; Tomelleri A.; Tufan A.; Can Kardas R.; Hinojosa-Azaola A.; Martín-Nares E.; Kawakami-Campos P.A.; Ragab G.; Hegazy M.T.; Direskeneli H.; Alibaz-Oner F.; Fotis L.; Sfriso P.; Govoni M.; La Torre F.; Cristina Maggio M.; Montecucco C.; De Stefano L.; Bugatti S.; Rossi S.; Makowska J.; Del Giudice E.; Emmi G.; Bartoloni E.; Hernández-Rodríguez J.; Conti G.; Nunzia Olivieri A.; Lo Gullo A.; Simonini G.; Viapiana O.; Wiesik-Szewczyk E.; Erten S.; Carubbi F.; De Paulis A.; Maier A.; Tharwat S.; Costi S.; Iagnocco A.; Sebastiani G.D.; Gidaro A.; Brucato A.L.; Karamanakos A.; Akkoç N.; Caso F.; Costa L.; Prete M.; Perosa F.; Atzeni F.; Guggino G.; Fabiani C.; Frediani B.; Giacomelli R.; Cantarini L.
    Objective: We aimed to evaluate the clinical usefulness of the systemic score in the prediction of life-threatening evolution in Still disease. We also aimed to assess the clinical relevance of each component of the systemic score in predicting life-threatening evolution and to derive patient subsets accordingly. Methods: A multicenter, observational, prospective study was designed including patients included in the Gruppo Italiano Di Ricerca in Reumatologia Clinica e Sperimentale Adult-Onset Still Disease Study Group and the Autoinflammatory Disease Alliance Network Still Disease Registry. Patients were assessed to see if the variables to derive the systemic score were available. The life-threatening evolution was defined as mortality, whatever the clinical course, and/or macrophage activation syndrome, a secondary hemophagocytic lymphohistiocytosis associated with a poor prognosis. Results: A total of 597 patients with Still disease were assessed (mean ± SD age 36.6 ± 17.3 years; male 44.4%). The systemic score, assessed as a continuous variable, significantly predicted the life-threatening evolution (odds ratio [OR] 1.24; 95% confidence interval [CI] 1.07–1.42; P = 0.004). A systemic score ≥7 also significantly predicted the likelihood of a patient experiencing life-threatening evolution (OR 3.36; 95% CI 1.81–6.25; P < 0.001). Assessing the clinical relevance of each component of the systemic score, liver involvement (OR 1.68; 95% CI 1.48–2.67; P = 0.031) and lung disease (OR 2.12; 95% CI 1.14–4.49; P = 0.042) both significantly predicted life-threatening evolution. The clinical characteristics of patients with liver involvement and lung disease were derived, highlighting their relevance in multiorgan disease manifestations. Conclusion: The clinical utility of the systemic score was shown in identifying Still disease at a higher risk of life-threatening evolution in a large cohort. Furthermore, the clinical relevance of liver involvement and lung disease was highlighted. (Figure presented.). © 2024 American College of Rheumatology.
  • No Thumbnail Available
    Item
    Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry
    (Elsevier Masson s.r.l., 2025) Sota J.; Ragab G.; AlMaglouth I.; Lopalco G.; Tufan A.; Direskeneli H.; Hinojosa-Azaola A.; Mayrink Giardini H.A.; Guerriero S.; Triggianese P.; Sfikakis P.P.; Piga M.; Ruscitti P.; Govoni M.; Iagnocco A.; Carubbi F.; Hernández-Rodríguez J.; Laymouna A.H.; Mahmoud A.A.-M.A.; Ghanema M.; Aboabat A.A.; Asfina K.N.; Alanazi F.; Morrone M.; Spedicato V.; Kucuk H.; Kardas R.; Alibaz Öner F.; Sevik G.; Torres-Ruiz J.; Kawakami-Campos P.A.; Parente de Brito Antonelli I.; Dammacco R.; Chimenti M.S.; Arida K.; Floris A.; Gentile M.; Ruffilli F.; Bellis E.; Alunno A.; Espinosa G.; Gentileschi S.; Gaggiano C.; Vitale A.; Caggiano V.; Lopez R.; Tarsia M.; Monti S.; Hatemi G.; Karakoç A.; Frassi M.; Giacomelli R.; Tharwat S.; Thabet M.; Ciccia F.; Emmi G.; Viapiana O.; Şahin A.; Sebastiani G.D.; Batu E.D.; Ozen S.; Sener S.; Opris-Belinski D.; Costi S.; Conforti A.; Cattalini M.; Bartoloni E.; Akkoç N.; Gunduz O.S.; Conti G.; Maier A.; Giardina A.; Li Gobbi F.; Parronchi P.; Sarzi Puttini P.; Breda L.; De Paulis A.; Carreño E.; La Torre F.; Więsik-Scewczyk E.; de-la Torre A.; Mejía-Salgado G.; Shahram F.; Guiducci S.; Maggio M.C.; Aragona E.; Rigante D.; Ciavarro A.; Önen F.; Erten; Insalaco A.; Del Giudice E.; Barone P.; Gicchino F.; Brucato A.; Lo Gullo A.; Mauro A.; Karamanakos A.; Balistreri A.; Mazzei M.A.; Frediani B.; Fabiani C.; Cantarini L.
    Objectives: Gender impact on phenotypical expression of Behçet's disease (BD) has been specifically investigated only in a few large-scale studies. The main goal of the study was to examine gender differences in a large cohort of patients affected by BD. Methods: Data were retrieved from the International AIDA Network Registry for BD. We assessed differences between males and females in terms of Behçet's syndrome Overall Damage Index (BODI), differences in the disease manifestations at onset and in the cumulative manifestations throughout disease course, as well as differences in the cardiovascular risk. Finally, predictive factors leading to major organ involvement were investigated. Results: In total, 1024 BD patients (567 males, 457 females) were enrolled in the study, with a male-to-female ratio of 1.24/1. Males displayed a significantly higher mean ± SD BODI (1.92 ± 2.09) at the last follow-up, compared to female patients (1.25 ± 1.87) (P < 0.0001). Uveitis (P < 0.0001) and vascular involvement (P = 0.0076) were significantly more frequent among males whereas female patients were significantly over-represented in arthralgia (P < 0.0001), arthritis (P = 0.00025), isolated headache (P < 0.0001), central nervous system (CNS) involvement (P = 0.040), and gastrointestinal involvement (P = 0.00046). Regarding cardiovascular risk, no differences between the two groups emerged (P = 0.617). Four variables were associated with the development of major organ involvement: male gender (OR = 2.104, P = 0.001), current treatment with biologic agents (OR = 2.257, P = 0.0003), origin from endemic countries (OR = 2.661, P = 0.0009), and disease duration (OR = 1.002, P = 0.024). Conclusion: BD displays a more severe course among males. This subgroup develops more irreversible damage and presents more frequently ocular and vascular involvement during disease course. On the other hand, female patients are prone to experience articular involvement, headache, CNS and gastrointestinal involvement. These data suggest the existence of a gender-driven disease expression. © 2024 The Author(s)
  • No Thumbnail Available
    Item
    Evaluation of Myocarditis in Patients With Still Disease: Clinical Findings From the Multicenter International AIDA Network Still Disease Registry
    (Journal of Rheumatology, 2025) Ruscitti P.; Di Cola I.; Vitale A.; Caggiano V.; Palumbo P.; Di Cesare E.; Torres-Ruiz J.; Guaracha-Basañez G.A.; Martín-Nares E.; Ciccia F.; Iacono D.; Riccio F.; Maggio M.C.; Tharwat S.; Hashad S.; Rigante D.; Ortolan A.; Mayrink Giardini H.A.; de Brito Antonelli I.P.; Cordeiro R.A.; Giacomelli R.; Navarini L.; Berardicurti O.; Conforti A.; Opris-Belinski D.; Sota J.; Gaggiano C.; Lopalco G.; Iannone F.; La Torre F.; Mastrorilli V.; Govoni M.; Ruffilli F.; Emmi G.; Biancalana E.; Sfikakis P.P.; Tektonidou M.; Hernández-Rodríguez J.; Gómez-Caverzaschi V.; Gündüz Ö.S.; Conti G.; Patroniti S.; Gidaro A.; Bartoli A.; Olivieri A.N.; Gicchino M.F.; Brucato A.L.; Dagna L.; Tomelleri A.; Campochiaro C.; De Paulis A.; Mormile I.; Casa F.D.; Direskeneli H.; Alibaz-Oner F.; Karamanakos A.; Dimouli A.; Ragab G.; Ahmed Mahmoud A.A.; Tufan A.; Kucuk H.; Kardas R.; Batu E.D.; Ozen S.; Wiesik-Szewczyk E.; Hinojosa-Azaola A.; Balistreri A.; Fabiani C.; Frediani B.; Cantarini L.
    Objective. We aimed to (1) evaluate the cardiac involvement, with a focus on myocarditis, in patients with Still disease included in the multicenter Autoinflammatory Disease Alliance (AIDA) Network Still disease registry; and (2) assess the predictive factors for myocarditis by deriving a clinical risk patient profile for this severe manifestation. Methods. A multicenter observational study was established, in which consecutive patients with Still disease in the AIDA Network Still disease registry were characterized by cardiac involvement. Cardiac involvement was defined according to the presence of pericarditis, tamponade, myocarditis, and/or aseptic endocarditis. Results. In total, 73 patients with Still disease and cardiac involvement were assessed (mean age 36.3 [SD 19.9] years; male sex, 42.5%), out of which 21.9% were children. The most common cardiac manifestation was pericarditis, occurring in 90.4% of patients; patients also presented with myocarditis (26%), and less frequently endocarditis (2.7%) and tamponade (1.4%). In comparing clinical features of patients with myocarditis to those without, significantly increased frequencies of skin rash and pleuritis, as well as higher systemic scores, were seen. Further, a higher mortality rate was shown in patients with myocarditis. In regression models, skin rash and the systemic score independently predicted the myocarditis. Conclusion. The characteristics of patients with Still disease and cardiac involvement were assessed in the AIDA Network. The most common feature was the pericarditis, but a more severe clinical picture was also reported in patients with myocarditis. The latter was associated with increased mortality rate and higher systemic score, identifying patients who should be carefully managed. © 2025 The Journal of Rheumatology.
  • No Thumbnail Available
    Item
    Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders
    (Taylor and Francis Ltd., 2025) Sota J.; Guerriero S.; Lopalco G.; Tufan A.; Ragab G.; AlMaglouth I.; Govoni M.; Sfikakis P.P.; Frassi M.; Vitale A.; Kardas R.C.; Triggianese P.; Chimenti M.S.; Aboabat A.A.; Piga M.; Monti S.; Sebastiani G.D.; Yildirim D.; Conforti A.; Gentileschi S.; Dammacco R.; Hinojosa-Azaola A.; Kawakami-Campos P.A.; Ruffilli F.; Torres-Ruiz J.; Thabet M.; Atig A.; Ruscitti P.; Cataldi G.; Viapiana O.; Hatemi G.; Karakoç A.; Costi S.; Iagnocco A.; Crisafulli F.; Fragoulis G.; Del Giudice E.; Hegazy M.T.; Paroli M.P.; Şahin A.; Morrone M.; Iannone F.; Opris-Belinski D.; Asfina K.N.; Barone P.; Gaggiano C.; Kucuk H.; Gicchino M.F.; Carubbi F.; Caggiano V.; Laskari K.; Tharwat S.; Direskeneli H.; Alibaz-Oner F.; Sevik G.; Maier A.; Laymouna A.H.; Emmi G.; Akkoç N.; Tarsia M.; Sbalchiero J.; Conti G.; Spinella R.; La Torre F.; Tombetti E.; Amin R.H.; Mauro A.; Karamanakos A.; Carreño E.; Fonollosa A.; Cattalini M.; Breda L.; de-la-Torre A.; Wiesik-Szewczyk E.; Cifuentes-González C.; Ozen S.; Mazzei M.A.; Tosi G.M.; Frediani B.; Balistreri A.; Batu E.D.; Gupta V.; Cantarini L.; Fabiani C.
    Purpose: The clinical relevance of human leukocyte antigen (HLA) subtypes such as HLA-B51 on Behçet’s disease (BD)-related uveitis and non-infectious uveitis (NIU) unrelated to BD remains largely unknown. Methods: Data were prospectively collected from the International AIDA Network Registry for BD and for NIU. We assessed differences between groups (NIU unrelated to BD and positive for HLA-B51, BD-related uveitis positive for HLA-B51 and BD-related uveitis negative for HLA-B51) in terms of long-term ocular complications, visual acuity (VA) measured by best corrected visual acuity (BCVA), anatomical pattern, occurrence of retinal vasculitis (RV) and macular edema over time. Results: Records of 213 patients (341 eyes) were analyzed. No differences in complications were observed (p = 0.465). With regard to VA, a significant difference was detected in median BCVA (p = 0.046), which was not maintained after Bonferroni correction (p = 0.060). RV was significantly more prevalent in NIU-affected patients who tested positive for HLA-B51, irrespective of the systemic diagnosis of BD (p = 0.025). No differences emerged in the occurrence of macular edema (p = 0.99). Conclusions: Patients with NIU testing positive for HLA-B51 exhibit an increased likelihood of RV throughout disease course, irrespective of a systemic diagnosis of BD. The rate of complications as well as VA are comparable between NIU cases unrelated to BD testing positive for HLA-B51 and uveitis associated with BD. Therefore, it is advisable to perform the HLA-B typing in patients with NIU or retinal vasculitis, even in the absence of typical BD features. © 2024 Taylor & Francis Group, LLC.